Drug Trial Radar · NCT05642949
Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
400
Planned (sponsor's estimate)
Start
Jan 23, 2023
Primary completion
Dec 31, 2025
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Minghui Pharmaceutical Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, pharmacokinetics, and anti-tumor efficacy of MHB036C in participants with advanced or metastatic solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
MHB036CDrug
MHB036C will be administered intravenously at a frequency of once every 3 weeks (Q3W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse eventsTime frame: From the day of the first dose of MHB036C to 30 days after the day of the last dose of MHB036C
- Number of participants with dose-limiting toxicitiesTime frame: 21 days after the first dose of MHB036C
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Pindara Private Hospital
Gold Coast, Queensland, Australia
Southern Oncology Clinical Research Unit
Adelaide, South Australia, Australia
Cabrini Health
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.